ID   FDOVL
AC   CVCL_B7MN
DR   cancercelllines; CVCL_B7MN
DR   Wikidata; Q112929560
RX   Patent=CN110835623A;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, China General Microbiological Culture Collection Center; CGMCC No.15484.
CC   Population: Chinese.
CC   Doubling time: 87 hours (Patent=CN110835623A).
CC   Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Ile1432Thr (c.4295C>T); Zygosity=Homozygous (Direct_author_submission).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu252del (c.754_756delCTC); ClinVar=VCV000998484; Zygosity=Heterozygous (Direct_author_submission).
CC   Miscellaneous: Age of donor and sequence variations by personal communication of Jiang W.
CC   Derived from site: Metastatic; Pelvic lymph node; UBERON=UBERON_0015876.
DI   NCIt; C105555; High grade ovarian serous adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   53Y
CA   Cancer cell line
DT   Created: 23-06-22; Last updated: 05-10-23; Version: 5
//
RX   Patent=CN110835623A;
RA   Jiang W., Yang H.-J., Yang W.-T., Xiang L.-B., Zheng Y.-Y., He T.-C., Pei X.;
RT   "Primary platinum-resistant human ovarian cancer cell line FDOVL, and
RT   preparation method and application thereof.";
RL   Patent number CN110835623A, 25-Feb-2020.
//